Phenoxybenzamine
- Atc Codes:C04AX02
- CAS Codes:63-92-3#59-96-1
- PHARMGKB ID:63-92-3#59-96-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Dibenzyran; Cyprus: Dibenyline; Germany: Dibenzyran; Greece: Dibenyline, Dibenzyran, Phenoxybenzamine; UK: Dibenyline, Phenoxybenzamine.
North America
USA: Dibenzyline.
Drug combinations
Chemistry
Phenoxybenzamine Hydrochloride: C~18~H~22~ClNO HCl. Mw: 340.29. (1) Benzenemethanamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-, hydrochloride; (2) N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine hydrochloride. CAS-63-92-3; CAS-59-96-1 (phenoxybenzamine).
Pharmacologic Category
Non-selective α-Adrenergic Blocking Agents: Antidote. (ATC-Code: C04AX02).
Mechanism of action
Produces long-lasting noncompetitive α-adrenergic blockade of postganglionic synapses in exocrine glands and smooth muscle. Relaxes urethra and increases opening of bladder.
Therapeutic use
Symptomatic management of pheochromocytoma.
Pregnancy and lactiation implications
Unknown whether phenoxybenzamine can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity.
Unlabeled use
Micturition problems associated with neurogenic bladder, functional outlet obstruction, and partial prostate obstruction. Treatment of hypertensive crisis caused by sympathomimetic amines.
Contraindications
Hypersensitivity to phenoxybenzamine or any component of the formulation. Conditions in which fall in blood pressure would be undesirable (e.g. shock).
Warnings and precautions
Cardiovascular effects (exaggerated hypotensive response and tachycardia) may occur when administered concurrently with compounds that stimulate both α- and β-adrenergic receptors or in setting of pheochromocytoma. Use with caution in obstructive cerebral or coronary atherosclerosis (marked reduction in blood pressure may induce ischemic symptoms), and in renal impairment. Can exacerbate symptoms of respiratory tract infections. Use with caution in the elderly. Not recommended for long-term use due to case reports of cancer in humans.